Nivolumab/Ipilimumab Plus CBM588 Generates Superior Efficacy in Metastatic RCC
November 7th 2022
The addition of CBM588 to the combination of nivolumab and ipilimumab produced superior response rates and a progression-free survival benefit vs nivolumab plus ipilimumab alone in previously untreated patients with metastatic renal cell carcinoma.